A randomized sequential trial of creatine in amyotrophic lateral sclerosis

Annals of Neurology

Volumn 53, Issue 4, 2003, Pages 437-445

  Groeneveld, Geert Jan ^a   Veldink, Jan H ^a   Van der Tweel, Ingeborg ^b   Kalmijn, Sandra ^a   Beijer, Cornelis ^c   De Visser, Marianne ^d   Wokke, John H J ^a   Franssen, Hessel ^a   Van den Berg, Leonard H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Het Diaconessenhuis ^*  (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NETHERLANDS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ANALYSIS; SURVIVAL RATE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; CREATINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 0037379650     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10554     Document Type: Article

References (52)

1. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118:707-719.
2. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330:585-591.
3. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347: 1425-1431.
4. Pedersen WA, Fu W, Keller JN, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998;44:819-824.
5. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
6. Drachman DB, Chaudhry V, Cornblath D, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;35:142-150.
7. Karpati G, Dalakas MC. Viral hide-and-seek in sporadic ALS: a new challenge. Neurology 2000;54:6-7.
8. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000;23:298-304.
9. Turner C, Schapira AH. Mitochondrial dysfunction in neurodegenerative disorders and ageing. Adv Exp Med Biol 2001; 487:229-251.
10. Kaal EC, Vlug AS, Versleijen MW, et al. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. J Neurochem 2000;74:1158-1165.
11. Wiedemann FR, Manfredi G, Mawrin C, et al. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002;80:616-625.
12. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998;18: 3241-3250.
13. Wallimann T, Hemmer W. Creatine kinase in non-muscle tissues and cells. Mol Cell Biochem 1994;133/134:193-220.
14. Hemmer W, Wallimann T. Functional aspects of creatine kinase in brain. Dev Neurosci 1993;15:249-260.
15. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001;8: 479-491.
16. Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann Neurol 2000;48:723-729.
17. Wick M, Fujimori H, Michaelis T, Frahm J. Brain water diffusion in normal and creatine-supplemented rats during transient global ischemia. Magn Reson Med 1999;42:798-802.
18. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
19. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
20. Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med Sci Sports Exerc 2000;32:291-296.
21. Bosco C, Tihanyi J, Pucspk J, et al. Effect of oral creatine supplementation on jumping and running performance. Int J Sports Med 1997;18:369-372.
22. Tarnopolsky M, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial myopathies. Muscle Nerve 1997;20:1502-1509.
23. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-857.
24. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
25. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Other Motor Neuron 2000;1:293-299.
26. Pocock SJ. Clinical trials. A practical approach. Chichester: Wiley, 1983.
27. Andres PL, Skerry LM, Thornell B, et al. A comparison of three measures of disease progression in ALS. J Neurol Sci 1996;139(suppl):64-70.
28. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) Phase I-II Study Group. Arch Neurol 1996;53:141-147.
29. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
30. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383-1388.
31. Armon C, Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci 1998;160(suppl 1):S37-S41.
32. Beijer C. Creatine measurement in serum and urine with an automated enzymatic method. Clin Chem 1993;39:1613-1619.
33. Freedman LS. Tables of the number of patients required in clinical trials using the log-rank test. Stat Med 1982;1:121-129.
34. Whitehead J. The design and analysis of sequential clinical trials. New York: Wiley, 1997.
35. PEST 4: Operating manual. The University of Reading, United Kingdom, 2000.
36. Greenhaff PL, Casey A, Short H, et al. Influence of oral creatine supplementation on muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci Lond 1993;84: 565-571.
37. Earnest CP, Snell PG, Rodriguez R, et al. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. Acta Physiol Scand 1995;153:207-209.
38. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci Lond 1992;83:367-374.
39. Rosenfeld J, Jackson CE, Smith J, et al. A pilot trial of ultrapure creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2(suppl 2):20 (Abstract).
40. Mazzini L, Balzarini C, Colombo R, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 2001;191:139-144.
41. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998;51:1629-1633.
42. Todd S, Whitehead A, Stallard N, Whitehead J. Interim analyses and sequential designs in phase III studies. Br J Clin Pharmacol 2001;51:394-399.
43. Whitehead J. Monotherapy trials: sequential design. Epilepsy Res 2001;45:81-87.
44. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116.
45. O'Gorman E, Beutner G, Wallimann T, Brdiczka D. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim Biophys Acta 1996;1276:161-170.
46. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998;156:65-72.
47. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998;153: 135-142.
48. Borthwick GM, Johnson MA, Ince PG, et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999;46:787-790.
49. Harris RC. Effects and safety of dietary and supplementary creatine. In: Paoletti R, Poli A, Jackson AS, eds. Creatine from basic science to clinical application. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000:33-39.
50. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49:561-574.
51. Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem 1998; 184:427-437.
52. Parise G, Parshad A, Wallimann T, Tarnopolsky MA. The effect of creatine mtCK and CreaT protein expression following resistance training. Can J Appl Physiol 2000;25:396.